Media

SpinalCure receives a grant from The Honda Foundation

We are pleased to announce that SpinalCure has received a $6,015 grant from The Honda Foundation. The Honda Foundation proudly supports organisations that are focused on helping others and in the promotion of innovation and new technologies. This grant will allow for the purchase of an examination bed and a camera for Project Edge. We’d like to thank Jason Everett from Scotts Honda for supporting us in the application process.

Australian Turf Club and SpinalCure

SpinalCure selected as 2017 Australian Turf Club Charity Partner of the Year



         

We are very pleased to announce that SpinalCure Australia has been chosen as this year’s Australian Turf Club Charity Partner of the Year.

Founded from the merger of the Australian Jockey’s Club and Sydney Turf Club in 2011, the Australian Turf Club (ATC) owns and operates premium Thoroughbred Racing, events and hospitality venues across Sydney.

“The Australian Turf Club prides itself on being one of the world’s most desirable destinations for thoroughbred racing, events and hospitality.”

The club places significant and genuine emphasis on community engagement, with a key area of focus on partnering with charities to provide opportunities for fundraising.

Given the unfortunate but very real connection between spinal cord injury and horse-racing and the high-level of support SpinalCure receives from some of the industry’s most notable riders and representatives, the synergistic partnership is fantastic step in the right direction for helping those injured while participating in one of our nation’s most cherished sporting traditions.

SpinalCure CEO Duncan Wallace commented “We are honoured and delighted to have been chosen as the ATC charity partner for this year. The awareness and support this will help generate will take us closer to the day when a spinal cord injury is no longer a life sentence. 

 It can be a long way from the saddle to the ground and sadly spinal cord injuries do occur. However, promising interventions that help restore feeling and function, such as the neurostimulation treatment that we are introducing to Australia via Project Edge, are under development and with the support of the ATC we will see them become available even sooner.

To help support us in our newly founded partnership, be sure to purchase your Longines Golden Slipper pins at the Rosehill Gardens racing events Mar 11 and 18 and stay tuned for more news and events to come throughout the year.

We are also looking for volunteers Mar 11 and 18 to help sell pins at Rosehill Gardens. 100% of proceeds from the sale of each $5 pin go to SpinalCure to support research for a cure.

Please contact Kathryn Borkovic by emailing [email protected] if you would like to help out.

Learn more about ATC   Donate to SpinalCure

Queensland researchers are launching a world-first clinical trial aimed at improving recovery from spinal cord injuries.

In the study, led by The University of Queensland and The Princess Alexandra (PA) Hospital, a new anti-inflammatory drug will be given to participants within hours of spinal trauma in an effort to minimise tissue damage.

Dr Marc Ruitenberg from the UQ School of Biomedical Sciences said when the spinal cord is injured, it becomes inflamed and this causes a lot of additional damage.

Dr Mark Ruitenberg
Dr Mark Ruitenberg PhD

“Up until now, doctors had no real treatment options to deal with this problem,” Dr Ruitenberg said.

“What we discovered in our animal studies is intravenous immunoglobulin (IVIg) therapy can reduce this harmful inflammation and, excitingly, significantly improve the recovery from serious spinal cord injuries.”

Spinal surgeon Dr Kate Campbell, who is heading up the trial with Dr Ruitenberg, said one of the great benefits of IVIg is that it is quite safe and already used in the hospital for other conditions.

“As a result, we have been able to quickly progress this treatment from the lab to the clinic,” she said.

The trial will run for three years and will aim to recruit 20 participants through the PA Hospital, which is Queensland’s primary centre for spinal injury care.

Queensland Health estimates that 90 people sustain spinal cord injuries in the state each year.

“Sadly, the summer holidays can be a busy time for spinal wards,” Dr Campbell said.

“It’s a time when people are travelling, heading to the beach and spending time outdoors, and unfortunately it’s a time when accidents occur.

“We hope this research will help the recovery of those who suffer these serious injuries.

“It can happen to anyone and we therefore urge people to be careful.”

Dr Ruitenberg’s pre-clinical work received funding support from the Wings for Life Foundation and SpinalCure Australia, while CSL Behring has provided IVIg and funding for the clinical trial.

Dr Andrea Douglas, Vice President R&D Strategy and External Affairs at CSL, said the use of intravenous immunoglobulin in this setting is a novel application for one of CSL’s flagship therapies.

“Spinal injuries are devastating, and with few options available to effectively treat the inflammation that occurs, we are very pleased that Dr Ruitenberg’s team are getting closer to finding a solution.”

Media: Dr Marc Ruitenberg, [email protected], 07 3346 7602; Kim Lyell, [email protected], 07 33465214, 0427 530647.